B3

• EPIC Y-Grade, LP (“EPIC” or “the Company”) today announced that it has completed the issuance of a new $1,075 million senior secured Term Loan B due 2029.
• The Company used the net proceeds from the Term Loan to repay its existing $989 million Term Loan B due 2027 and repay its existing $77 million facility on a standalone propane line.
• As part of the transaction, the Company also increased its current super-priority revolving credit facility to $70 million from $40 million and extended the facility’s maturity date to 2029.
• We’re pleased that companies are continuing to expand their y-grade positions in Corpus Christi with EPIC Midstream.”

• The latest of its test platforms for validating the reliability, high performance, and interoperability of Ethernet technologies, the B3 Appliance will debut at the 2024 OFC Conference and Exhibition in San Diego, March 26-28 in booth #1515.
• As a vendor-neutral test system, the Spirent B3 800G Appliance will help accelerate 800G deployments to enable the networking industry to power new applications running AI/ML.
• “High density 800G test solutions are critical for validating the performance of 800G modules,” said Gerry Wong, CEO at CIG.
• In today’s environment, where time-to-market of next-gen solutions is condensed, test and assurance solutions capable of evaluating beta technologies are invaluable.

• BARCELONA, Spain, Feb. 29, 2024 /PRNewswire/ -- At MWC Barcelona 2024, Huawei launched a new flagship collaborative whiteboard, the IdeaHub ES2 Plus.
• The product, which boasts several technical breakthroughs and product innovations, is expected to set a benchmark for the newest generation of digital and intelligent enterprise office solutions.
• In addition to the IdeaHub ES2 Plus, Huawei Intelligent Collaboration has launched a range of products to cater to all office scenarios and boost organizational efficiency.
• These include the IdeaHub ES2, IdeaHub B3 for lightweight enterprise offices, and IdeaPresence LED giant-screen display for high-end large meeting rooms.

• Vitamin patches are trending on social media and advertised in posts and podcasts.
• With patches marketed for sleep, detox, immunity and hangovers, they are being talked up as near magical fix-all stickers.

What are vitamin patches?

• Vitamin patches are adhesives designed to deliver vitamins or nutrients to your bloodstream directly through the skin.
• Patches promising an energy boost offer caffeine, taurine, gluconolactone, green tea extract and vitamins B3, B5 and B6.

Do they work and are they safe?

• Vitamins are generally approved as listed medicines, meaning the ingredients have been assessed for safety but not for efficacy (whether they do what they promise).
• However, there are no items listed as vitamin patches on the Australian Register of Therapeutic Goods.

• Ordinarily, to be absorbed through the skin a chemical needs to be lipophilic, meaning it likes fats and oils more than water.
• So, the form in which the vitamins have been produced and supplied will dictate whether they will get into the skin.
• The health condition called scurvy is thought to occur when daily vitamin C intake drops lower than 7 milligrams per day.
• The recommended daily intake of vitamin C is around 45 milligrams per day – more if a woman is breastfeeding.

Read more:
Is TikTok right – will eating three carrots a day really give me a natural tan?

Why not just take a tablet?

• One selling point used by the marketers is that patches are a “cleaner” form of vitamins.
• A vitamin in tablet or gummy form will contain inactive ingredients called excipients.
• But many patches don’t list all their ingredients – just the active vitamins – so this claim can not be tested.

Should you buy them?

As there are no vitamin patches approved by the TGA in Australia, you should not buy them. If at some point in the future they become listed medicines, it will be important to remember that they may not have been assessed for efficacy. If you remain curious about vitamin patches, you should discuss them with your doctor or local pharmacist.

• He is a Fellow of the Royal Australian Chemical Institute, a member of the Australasian Pharmaceutical Science Association, and a member of the Australian Institute of Company Directors.
• Nial regularly consults to industry on issues to do with medicine risk assessments, manufacturing, design, and testing.